National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2010 - specification under subsection 84AAA(2) (No. PB 119 of 2010)

Administered by Department of Health, Disability and Ageing

Legislation au F2010L03116 Not in force Legislative Instrument

Legislation content

 

 

 

EXPLANATORY STATEMENT

 

NATIONAL HEALTH ACT (PHARMACEUTICAL BENEFITS – EARLY SUPPLY) AMENDMENT DECEMBER 2010 - SPECIFICATION UNDER SUBSECTION 84AAA(2)

 

INSTRUMENT NUMBER PB 119 OF 2010

NATIONAL HEALTH ACT 1953

 

This instrument amends the determination that lists the medicines for which Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements will not apply when the next supply of the same medicine is obtained within 20 days.

 

Part VII of the National Health Act 1953 (the Act) is the legislative basis for the PBS by which the Commonwealth provides reliable, timely, and affordable access to a wide range of medicines for all Australians.

 

Subsection 85(1) provides that benefits are to be provided by the Commonwealth in accordance with Part VII in respect of pharmaceutical benefits.

 

Drugs and medicinal preparations to which Part VII applies are declared by the Minister by legislative instrument under subsection 85(2).

 

Subsection 85(3) authorises the Minister by legislative instrument to determine by reference to strength, type of unit, size of unit, or otherwise, the form or forms of a listed drug.  Subsection 85(5) authorises the Minister by legislative instrument to determine the manner of administration of a form of a listed drug where the form has been determined under subsection 85(3).  Subsection 85(6) authorises the Minister by legislative instrument to determine a brand of a pharmaceutical item.

 

These determinations govern what constitutes a pharmaceutical benefit (defined in subsection 84(1)) under Part VII of the Act.

 

Paragraph 85A(2)(a) authorises the Minister to determine the maximum quantity or number of units that may, in one prescription, be directed to be supplied for all purposes or for a particular purpose.  Paragraph 85A(2)(b) authorises the Minister to determine the maximum number of occasions on which the supply may, in one prescription, be directed to be repeated for all purposes or a particular purpose.

 

Paragraph 84C(4A)(a) of the Act refers to repatriation pharmaceutical benefits supplied under the scheme established under section 91 of the Veterans’ Entitlements Act 1986 or supplied in accordance with a determination made under paragraph 256(1)(c) of the Military Rehabilitation and Compensation Act 2004.

 


 

Subsection 84AAA(1) of the Act provides that a supply of a pharmaceutical benefit to a person is an early supply of a specified pharmaceutical benefit if:

  • The supply is made within 20 days after the day of a previous supply of the same pharmaceutical benefit to the person (whether or not the previous supply is a supply of a kind described in paragraph 84C(4A)(a));
  • The pharmaceutical benefit is specified in an instrument under subsection 84AAA(2); and
  • The supply does not result from a prescription originating from a hospital or a day hospital facility.

 

The early supply of a specified pharmaceutical benefit includes a supply of a pharmaceutical benefit specified in the instrument, as either a pharmaceutical benefit or a repatriation pharmaceutical benefit within 20 days of a previous supply of the same pharmaceutical benefit to the same person.  The repatriation pharmaceutical benefits supplied under the Repatriation Pharmaceutical Benefits Scheme which are subject to the provisions for early supply of a specified pharmaceutical benefit are those where the repatriation pharmaceutical benefit is the same as a specified pharmaceutical benefit for supply under the PBS.

 

‘Hospital’ is defined in the subsection 3(1) of the Health Insurance Act 1973 to mean a recognised hospital, a private hospital, or a hospital that is declared by the Minister to be a hospital for the purposes of that definition.  ‘Day hospital facility’ is defined in subsection 4(1) of the National Health Act 1953.

 

Subsections 84C(4) and 84C(4A) of the Act regulate the supply or repeated supply of pharmaceutical benefits and repatriation pharmaceutical benefits which are be taken into account in totalling amounts charged for the purpose of demonstrating eligibility for a safety net concession card or safety net entitlement card.

 

Subsection 84C(4AA) of the Act provides that the amount charged for an early supply must not be taken into account when determining eligibility for a concession card or entitlement card, if the supply is for a pharmaceutical benefit specified in the instrument and the supply is not a supply of an out-patient medication.  That is, an amount charged for an early supply is excluded when calculating whether the safety net threshold has been reached.

 

The amount charged for an early supply of a concession card prescription and entitlement prescription are the general benefit prescription and concessional benefit prescription amounts, respectively.  This does not apply for hospital, day hospital, or outpatient prescriptions.  Out-patient medication is defined in subsection 84(1) of the Act to mean a drug or medicinal preparation supplied through the out-patient department of a public hospital.  

 


Subsection 87(2) of the Act sets out the amounts to be charged to patients for the supply of pharmaceutical benefits.  These provisions form the basis for the patient charges which apply for general benefit prescriptions (currently up to $33.30), concessional benefit prescriptions (currently $5.40), concession card prescriptions (currently $5.40), and entitlement prescriptions (free).  The provisions also set the charges for prescriptions which are an early supply of a pharmaceutical benefit.  The charges for prescriptions for repatriation pharmaceutical benefits are treated as for concessional benefit prescriptions and entitlement prescriptions, including in relation to early supply.

 

Section 99 of the Act regulates the amounts that pharmacists and medical practitioners who are approved under the Act to supply pharmaceutical benefits, are entitled to be paid by the Commonwealth for supplying those benefits.  This includes the amount to be paid for prescriptions which are an early supply of a pharmaceutical benefit.

 

This legislative instrument is made under subsection 84AAA(2) of the Act. Subsection 84AAA(2) of the Act provides that the Minister may specify, by legislative instrument, pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act.  Subsection 84AAA(3) provides that the instrument may specify a pharmaceutical item by reference to the circumstances in which a pharmaceutical benefit that has the pharmaceutical item is supplied or any other circumstances in relation to a pharmaceutical benefit that has the pharmaceutical item.

 

The pharmaceutical items in the Instrument are specified by the Minister who can take into account the advice of the Pharmaceutical Benefits Advisory Committee (PBAC).  The PBAC is the independent expert body, established by section 100A of the Act, which makes recommendations to the Minister about which drugs and medicinal preparations should be available as pharmaceutical benefits.  PBAC members are selected from consumers, health economists, practising community pharmacists, general practitioners, clinical pharmacologists and specialists, with at least one member selected from each of those interests or professions.  Remaining members are persons whom the Minister is satisfied have qualifications and experience in a field relevant to the functions of the PBAC, and that would enable them to contribute meaningfully to the deliberations of the PBAC.

 

Section 101 of the Act sets out the functions of the PBAC in relation to making recommendations and providing advice to the Minister regarding the medicines to be declared as pharmaceutical benefits under Part VII of the Act, and any other matter concerning Part VII of the Act referred to the PBAC by the Minister.

 

Subsection 101(3AA) requires the PBAC to make recommendations to the Minister about what should be specified in an instrument made under 84AAA(2).

 

This Instrument was made on 29 November 2010 and commences on 1 December 2010.

 

This Instrument is a legislative instrument for the purposes of the Legislative Instruments Act 2003.

 

Details of the Instrument are set out in Attachment 1.

 

This Instrument amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - Specification Under Subsection 84AAA(2), PB No. 30 of 2009.  The Instrument amends the list of items specified under subsection 84AAA(2).  Details of the changes effective from 1 December 2010 are set out in Attachment 2.  The additional pharmaceutical items effective from 1 December 2010 are described in Table 1, and the removed pharmaceutical items are described in Table 2.

 

Consultation regarding implementation of the arrangements for early supply of specified pharmaceutical benefits occurred with Medicare Australia, the Department of Veterans’ Affairs, the Medical Software Industry Association, and peak pharmacy organisations (including the Pharmacy Guild of Australia, the Pharmaceutical Society of Australia, the Australian Association of Consultant Pharmacy, and the Society of Hospital Pharmacists of Australia).  The PBAC has provided advice on which pharmaceutical benefits should be specified in the Instrument.


ATTACHMENT 1

Section 1: provides that the name of the Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2010 - specification under subsection 84AAA(2) and that the Instrument may also be cited as
No. PB 119 of 2010.

 

Section 2: provides that the Instrument commences on 1 December 2010.

 

Section 3: provides that this Amendment amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 - specification under subsection 84AAA(2), No. PB 30 of 2009.

 

Schedule 1:  specifies the pharmaceutical items in the pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b) of the Act by reference to the drug or medicinal product as declared under subsection 85(2), the form (strength, type, size, etc.) as determined under subsection 85(3), manner of administration as determined under subsection 85(5), maximum quantity or number of units as determined under paragraph 85A(2)(a); maximum repeats as determined under paragraph 85A(2)(b), and any other circumstances that apply under paragraph 84AAA(3)(b) of the Act.

 

ATTACHMENT 2

 

 

Table 1.  Items added

Degarelix

 

Table 2.  Items deleted

Anakinra

 

 

Overview

The National Health (Pharmaceutical Benefits – Early Supply) Amendment December 2010 - Specification under Subsection 84AAA(2) was enacted to address the problem of ensuring that the Pharmaceutical Benefits Scheme (PBS) Safety Net entitlements do not apply when a patient obtains the next supply of the same medicine within 20 days. The Act, National Health Act 1953, provides the legislative basis for the PBS, which ensures reliable, timely, and affordable access to a wide range of medicines for Australians. The Minister, authorised by the Act, uses legislative instruments to specify pharmaceutical benefits and manage the supply of these benefits. The policy objective of this amendment is to refine the list of pharmaceutical items that are subject to the early supply provisions, ensuring that patient costs are appropriately managed under the PBS while maintaining efficient and effective healthcare delivery. This amendment was made by the Minister under the authority granted by subsection 84AAA(2) of the National Health Act 1953. The Pharmaceutical Benefits Advisory Committee (PBAC) provided expert advice to the Minister on the specification of pharmaceutical benefits, ensuring that the amendments align with current healthcare needs and cost-effectiveness. The changes effective from 1 December 2010 include the addition of Degarelix and the removal of Anakinra from the list of specified pharmaceutical benefits, reflecting adjustments based on clinical and economic considerations.

Scope and Application

The National Health (Pharmaceutical Benefits – Early Supply) Amendment December 2010 applies to the supply of pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS) administered by the Commonwealth of Australia. It specifically addresses early supplies of specified pharmaceutical benefits, meaning supplies made within 20 days of a previous supply of the same medicine to the same person, and excludes supplies resulting from prescriptions originating from hospitals or day hospital facilities. This Act amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009, specifying certain pharmaceutical items for which early supply provisions apply. The Act is applicable nationally, as it pertains to the Commonwealth’s administration of the PBS, which is designed to ensure all Australians have reliable, timely, and affordable access to a wide range of medicines. The Act does not extend or restrict its application through subordinate instruments, but it relies on the Pharmaceutical Benefits Advisory Committee (PBAC) for expert advice on the specification of pharmaceutical items. The PBAC, composed of members from various health-related professions and interests, provides recommendations to the Minister regarding the specification of pharmaceutical benefits under the Act.

Key Provisions

The primary operative sections of the National Health (Pharmaceutical Benefits – Early Supply) Amendment December 2010 (No. PB 119 of 2010) are contained within subsection 84AAA(1) and 84AAA(2) of the National Health Act 1953. Subsection 84AAA(1) specifies the conditions under which a supply of a pharmaceutical benefit qualifies as an early supply, namely if it is made within 20 days of a previous supply of the same pharmaceutical benefit to the same person and the pharmaceutical benefit is specified in an instrument under subsection 84AAA(2). Subsection 84AAA(2) authorises the Minister to specify by legislative instrument pharmaceutical benefits for the purposes of paragraph 84AAA(1)(b). The instrument, which commenced on 1 December 2010, amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009 (No. PB 30 of 2009), specifying new pharmaceutical items that are subject to the early supply provisions. The Act imposes several obligations on parties involved in the Pharmaceutical Benefits Scheme (PBS). Firstly, the Minister is required to consult with the Pharmaceutical Benefits Advisory Committee (PBAC) for advice on which pharmaceutical benefits should be specified in the instrument. The PBAC, an independent expert body, provides recommendations to the Minister on the inclusion of drugs and medicinal preparations in the PBS. Furthermore, pharmacists and medical practitioners who are approved to supply pharmaceutical benefits under the Act must adhere to the patient charges and amounts payable by the Commonwealth as outlined in the Act. These obligations ensure that the PBS operates efficiently and effectively. In terms of consequences for breach, the Act does not explicitly outline specific offences, penalties, or civil/criminal consequences for non-compliance with the early supply provisions. However, the overarching regulatory framework of the National Health Act 1953 and related legislation provides a basis for enforcement. Non-compliance with the patient charges, amounts payable, or other provisions of the Act could lead to legal action, fines, or other penalties as prescribed by relevant laws. The specific penalties would depend on the nature and severity of the breach, and would be determined in accordance with the applicable legal provisions. Overall, the National Health (Pharmaceutical Benefits – Early Supply) Amendment December 2010 (No. PB 119 of 2010) establishes the conditions for early supply of specified pharmaceutical benefits under the PBS, imposes obligations on the Minister, PBAC, and approved suppliers, and provides a basis for enforcement in case of non-compliance with the provisions of the Act.

Legal classification tags

Area of Law
Health Law
Pharmaceutical Law
Instrument
Legislative Instrument
Concepts
Definitions & Interpretation
Regulatory Standards
Reporting & Disclosure Obligations
Prohibited Conduct

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.